Cargando…

Development of focal segmental glomerulosclerosis in a patient with Familial Mediterranean Fever resistant to colchicine therapy under treatment with Canakinumab

Detalles Bibliográficos
Autores principales:	Barut, K, Canpolat, N, Adrovic, A, Cicek, R, Sinoplu, AB, Arslan, E, Kasapcopur, O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599968/ http://dx.doi.org/10.1186/1546-0096-13-S1-P95

Ejemplares similares

Articular involvement in childhood Familial Mediterranean Fever
por: Barut, K, et al.
Publicado: (2015)

Familial Mediterranean Fever in childhood: a single center experience
por: Barut, K, et al.
Publicado: (2015)

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

A case of systemic juvenile idiopathic arthritis with pulmonary hemosiderosis secondary to recurrent macrophage activation syndrome or a new autoinflammatory syndrome?
por: Barut, K, et al.
Publicado: (2015)

Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
por: Berdeli, Afig, et al.
Publicado: (2019)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF
por: Gul, A, et al.
Publicado: (2015)

Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study
por: Yoshida, Shuhei, et al.
Publicado: (2023)

Indications and efficacy of canakinumab in Familial Mediterranean Fever: report of three cases
por: Tsinti, Maria, et al.
Publicado: (2014)

Increased frequency of psoriasis in the families of subjects with childhood Familial Mediterranean Fever
por: Barut, Kenan, et al.
Publicado: (2014)

Epidemiology of colchicine resistant Familial Mediterranean Fever disease (CrFMF) in Turkey
por: Turgay, S, et al.
Publicado: (2015)

Screening for inherited metabolic disorders in patients with Familial Mediterranean Fever
por: Kiykim, E, et al.
Publicado: (2015)

Increased Frequency of Febrile Seizures in Two Periodic Fever Syndromes: Familial Mediterranean Fever and PFAPA Syndrome
por: Kılıç, Hüseyin, et al.
Publicado: (2022)

The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: the Greek experience in 12 patients
por: Laskari, K, et al.
Publicado: (2015)

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

Screening of free carnitine and acyl-carnitine status in patients with Familial Mediterranean Fever
por: Kiykim, E, et al.
Publicado: (2015)

The patient experience of Colchicine Resistant-Familial Mediterranean Fever (cr-FMF)
por: Dandekar, P, et al.
Publicado: (2015)

The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
por: Sozeri, Betul, et al.
Publicado: (2016)

PReS-FINAL-2195: The comparison of the efficacy of once and twice daily dosage of colchicine in pediatric patients with Familial Mediterranean Fever
por: Polat, A, et al.
Publicado: (2013)

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
por: Ozen, Seza, et al.
Publicado: (2020)

Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment
por: Alpa, Mirella, et al.
Publicado: (2015)

Genetics of focal segmental glomerulosclerosis
por: Woroniecki, Robert P., et al.
Publicado: (2007)

Pathophysiology of focal segmental glomerulosclerosis
por: Reidy, Kimberly, et al.
Publicado: (2007)

Pathogenesis of Focal Segmental Glomerulosclerosis
por: Lim, Beom Jin, et al.
Publicado: (2016)

Unwinding focal segmental glomerulosclerosis
por: Peev, Vasil, et al.
Publicado: (2017)

Secondary Focal Segmental Glomerulosclerosis: From Podocyte Injury to Glomerulosclerosis
por: Kim, Jae Seok, et al.
Publicado: (2016)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever
por: Karabulut, Yusuf, et al.
Publicado: (2022)

Actinic Granuloma with Focal Segmental Glomerulosclerosis
por: Phasukthaworn, Ruedee, et al.
Publicado: (2016)

Alendronate-associated focal segmental glomerulosclerosis
por: Prikis, Marios, et al.
Publicado: (2009)

Interferon Induced Focal Segmental Glomerulosclerosis
por: Kayar, Yusuf, et al.
Publicado: (2016)

Focal Segmental Glomerulosclerosis in Waldenström's Macroglobulinemia
por: Batra, Akshee, et al.
Publicado: (2020)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever
por: Calligaris, Lorenzo, et al.
Publicado: (2007)

Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
por: El Hasbani, Georges, et al.
Publicado: (2019)

Improvement of Liver Involvement in Familial Mediterranean Fever After the Introduction of Canakinumab: A Case Report
por: Massaro, Maria Grazia, et al.
Publicado: (2020)

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
por: Kacar, Mark, et al.
Publicado: (2020)

NPHS2 variation in focal and segmental glomerulosclerosis
por: Tonna, Stephen J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_17gc12pv4ri4bdeapv04o0ju1m